What initially started as infectious respiratory symptoms in the Wuhan region of China, turned out a globally acclaimed pandemic known as Coronavirus Disease-2019 (COVID-19). It is caused by a coronavirus, 2019-nCoV, known as severe acute respiratory syndrome-related coronavirus SARS-CoV-2. As of May 15, 2020, more than 4,494,873 confirmed cases and over 305,976 confirmed deaths were recorded worldwide spanning to more than 216 countries or territories (Figure ). Additionally, people's lives around the globe have suffered as a consequence of compulsory quarantines/isolations/restrictions. The worldwide upshot of the COVID-19 pandemic could possibly bring key tasks to healthcare systems and have across-the-board consequences on economics globally. The coronaviruses (CoVs) belong to the subfamily Orthocoronavirinae, are relatively large with genome size 26 to 32 kilobases, having helical symmetry nucleocapsid with a positive-sense singlestranded RNA genome. The viral capsid is studded with distinctive glycoprotein spikes, which in electron micrographs generate an image expressive of the solar corona, from which their name derives (Figure ). The glycosylated spike (S) protein (structural protein) mediates the host cell entry via binding to a protein (receptor)known as angiotensin-converting enzyme 2 (ACE2) positioned on the surface membrane of host cells primed by the host serine protease TMPRSS211. This interface communication between ACE2 receptor and viral S protein is of high value since it recruits the infection process. Afterward, the viral polyproteins are translated using host cell translation machinery followed by cleavage into effector proteins by viral proteinases, coronavirus main protease (3CLpro), and papainlike protease (PLpro). Subsequently, viral RNA-dependent RNA polymerase (RdRp), catalyzes the synthesis of a full-length negative-strand RNA template to be utilized to construct more viral genomic RNA. Such critical and pandemic situation demands immediate therapeutic rescue; however, no proven therapy has been established so far. This causes a shift in the policy "from drug discovery to drug repurposing" where clinically proven drugs are reutilized for new indications. In this course, in vitro or in silico drug screening tool identified few FDA-approved drugs as a possible treatment for COVID-19. Towards this end, chloroquine or hydroxychloroquine (debatable), lopinavir/ritonavir, and favilavir were promising candidates and are in clinical trials for the treatment of SARS-CoV-2. 17,18